Skip to main content
. 2020 Jan 16;16(5):827–837. doi: 10.7150/ijbs.32460

Figure 3.

Figure 3

Effect of miR-9 plus cisplatin on HCC cell viability and proliferation in vivo. (A) Gross morphology of subcutaneous xenograft tumors. The tumors were treated with control, cisplatin, miR-9 mimic, or cisplatin plus miR-9 mimic. (B) Growth curves of xenograft tumors treated with control, cisplatin, miR-9 mimic, or cisplatin plus miR-9 mimic (n = 4 per group). *P < 0.05,***P < 0.001 vs Control. (C) The weights of mice were measured on day 0-15 which was treated with control, cisplatin, miR-9 mimic, or cisplatin plus miR-9 mimic. (D) Ki-67 staining in the treatment groups (×40 magnification) and rate of Ki-67 positive staining. Bottom panels depict the insets of the top panels (×100 magnification). (E) TUNEL of apoptosis in the treatment groups (×40 magnification). Bottom panels depict the insets of the top panels (×100 magnification). *vs. control, #vs. cisplatin plus miR-9 mimic, *P < 0.05, **P < 0.01, ***P < 0.001, ##P < 0.01, ###P < 0.001. IHC-P, immunohistochemistry-positive.